International symposium on geroprotectors: Practical Applications of Aging Research for Drug Discovery (free registration) Aging lies at the core of every age-related disease and affects every person on the planet. It represents an unbearable toll on the economies of the developed countries resulting in over two trillion dollars in direct medical costs, costs of caring and lost productivity in the US and EU alone. Yet, pharmaceutical companies fail to see the practical applications of aging research as many early experiments with drugs that held promise in slowing the aging processes resulted in commercial failures and write offs. Lack of business models, regulation and absence of a clear set of aging biomarkers make it difficult for large pharmaceutical companies to fully engage in aging research. Unlike other events that are geared towards academia or have a broad range of topics, this forum intends to focus on drug discovery and pharmaceuticals that may have a role in postponing the aging processes, preventing the age-related diseases and evaluating the effectiveness of various small molecules with geroprotective properties. The event will showcase the research projects in aging research to the leaders of the pharmaceutical industry. The symposium will comprise into the three sessions relevant to the drug discovery companies. Each session will be chaired by the top expert in the field: Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design Session II: Drugs with the potential geroprotective properties Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy? Session IV: Trends in Aging Research and Drug Discovery

1. International Symposium on Geroprotectors: Practical applications of aging research for drug discovery
23.09, Tuesday: Keynotes/General
08.00 - 08.30
Advances in aging biomarkers and
drugs with geroprotective properties Brian Kennedy Director, CEO
Buck Institute for
Aging Research USA
08.30 - 09.00
New approaches in aging diagnostics
and interventions Charles Cantor Professor Boston University USA
09.00 - 9.30 TBD Nir Barzilai Director
Albert Einstein
College of Medicine USA
9.30-10.30
10.30 - 11.00
Novel methods for selecting targeted
drugs for personalized medicine in
oncology Anton Buzdin President, CEO
Pathway
Pharmaceuticals
Hong
Kong
11.00 - 11.30
Bioinformatic analysis of the “omics”
data from long-lived animals for
geroprotector discovery
Joao Pedro De
Magalhaes Lab Head
University of
Liverpool UK
11.30 - 12.00
In silico screening for novel drugs with
geroprotective properties
Alexander
Zhavoronkov Director
The Biogerontology
Research
Foundation UK
Lunch
13.30-14.15 TBD Dr. Jörg Reinhardt Chairman Novartis Global
Session II: Drugs with the potential geroprotective properties Session Chair: TBD
14.30 - 15.00
Using novel isotopically-fortified organic
compounds to slow down the aging
processes
and treat age-related diseases Robert Molinari CEO Retrotope, Inc USA
15.00 - 15.30
Advances in the Advanced Glycation
Endproduct (AGE) breakers William Bains
Head of the SENS
Laboratory Cambridge UK
15.30 - 16.00 Overview of the possible geroprotectors Sven Bulterijs
Post-grad
researcher Yale University USA
16.00 - 16.30 Coffee Break
16.30 - 17.00
Applied Epigenetics of Aging and
Longevity Olga Kovalchuk Professor, Lab Head
University of
Lethbridge Canada
24.09, Wednesday: Keynotes/General
08.00 - 08.30 Rapamycin and other geroprotectors
Mikhail
Blagosklonny
Professor, editor-in-
chief of Aging Rosewell Park, NY USA
08.30 - 09.00 TBD Blanka Rogina
Director Genetics &
Developmental
Biology Graduate
Program
University of
Connecticut USA
09.00 - 09.30 TBD James Kirkland Professor Mayo Clinic USA
09.30 - 10.00
How to Solve Genetic Disease on a
Population Scale Barry Merriman
Professor/ Lead
System Architect,
CSO
UCLA/Thermo
Fisher Scientific USA
10.00 - 10.30 Coffee Break
10.30 - 11.00
Lessons learned from the EU FP7
MARK‐AGE Project Alexander Bürkle
Professor, MARK-
AGE Co-ordinator
University of
Konstanz Germany
11.00-11.30
Comparative genomics of aging and
longevity Vadim Gladyshev
Professor,
Department of
Medicine, Harvard
Medical School
Director of Redox
Medicine, Medicine,
Brigham And
Women's Hospital Harvard USA
11.00 - 11.30
Gene expression patterns in progeria
and age-related diseases
Antonei Benjamin
Csoka Assoc. Professor Howard University USA
11.30 - 12.00
Genetic and Epigenetic Biomarkers of
Aging Alexey A Moskalev
Professor, head of
the laboratory
Moscow Institute of
Physics and
Technology Russia
Lunch
13.30-14.15 TBD
Prof. Patrick
Aebischer President
Ecole
Polytechnique
Fédérale de
Lausanne (EPFL) SW
Session IV: Trends in Aging Research for Drug Discovery Session Chair: Richard Faragher, PhD
14.30 - 15.00
Ageing Research and Regenerative
Medicine Industry Outlook
Charles Groome
and Geoffrey
Furlonger
Head of
Communications Aging Analytics UK
15.00 - 15.30
Industry Partnerships for Ageing
Research David Brindley
Research Fellow in
Cell Therapy
Commercialization /
Researcher
Harvard Stem Cell
Institute / University
of Oxford,
NDORMS UK
15.30 - 16.00
Big Data in Biomedicine: Applying
machine learning to predict the
outcomes of biomedical research
projects Dmitry Kaminskiy
Director, Senior
Partner
Deep Knowledge
Ventures
Hong
Kong
16.00 - 16.30 Coffee Break
16.30 - 17.00 TBD Richard Faragher Professor
University of
Brighton UK
Backup keynote speaker (23 or 24)
TBD
New drug discovery: AK-1 for
radioprotection, AK-2 for antiviral and
AK-3 for anti-aging Grace Wong CEO Actokine USA
ROUND TABLE (Bhupinder Bullar to organize): how can large pharma engage in aging research?
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug
design; Session Chair: Joao Pedro Megalhaes, PhD
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD